Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $22.2100 (-2.03%) ($21.8200 - $22.5400) on Thu. Jul. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.58% (three month average) | RSI | 69 | Latest Price | $22.2100(-2.03%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 7.9% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.29% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-17%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.29% (StdDev 6.58%) | Hourly BBV | 0 () | Intraday Trend | -0.8% | | | |
|
5 Day Moving Average | $22.62(-1.81%) | 10 Day Moving Average | $22.46(-1.11%) | 20 Day Moving Average | $20.85(6.52%) | To recent high | -8% | To recent low | 112.3% | Market Cap | $2.813b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |